These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 32026316)

  • 1. Blockade of HSP70 by VER-155008 synergistically enhances bortezomib-induced cytotoxicity in multiple myeloma.
    Huang L; Wang Y; Bai J; Yang Y; Wang F; Feng Y; Zhang R; Li F; Zhang P; Lv N; Lei L; Hu J; He A
    Cell Stress Chaperones; 2020 Mar; 25(2):357-367. PubMed ID: 32026316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.
    Hu J; Van Valckenborgh E; Xu D; Menu E; De Raeve H; De Bruyne E; Xu S; Van Camp B; Handisides D; Hart CP; Vanderkerken K
    Mol Cancer Ther; 2013 Sep; 12(9):1763-73. PubMed ID: 23832122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells.
    Massey AJ; Williamson DS; Browne H; Murray JB; Dokurno P; Shaw T; Macias AT; Daniels Z; Geoffroy S; Dopson M; Lavan P; Matassova N; Francis GL; Graham CJ; Parsons R; Wang Y; Padfield A; Comer M; Drysdale MJ; Wood M
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):535-45. PubMed ID: 20012863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
    Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
    Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells.
    Wada N; Kawano Y; Fujiwara S; Kikukawa Y; Okuno Y; Tasaki M; Ueda M; Ando Y; Yoshinaga K; Ri M; Iida S; Nakashima T; Shiotsu Y; Mitsuya H; Hata H
    Int J Oncol; 2015 Mar; 46(3):963-72. PubMed ID: 25530098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stew in its Own Juice: Protein Homeostasis Machinery Inhibition Reduces Cell Viability in Multiple Myeloma Cell Lines.
    de Oliveira MB; Sanson LFG; Eugenio AIP; Barbosa-Dantas RSS; Colleoni GWB
    Curr Mol Med; 2019; 19(2):112-119. PubMed ID: 30834832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors.
    Jones RJ; Singh RK; Shirazi F; Wan J; Wang H; Wang X; Ha MJ; Baljevic M; Kuiatse I; Davis RE; Orlowski RZ
    Front Immunol; 2020; 11():1816. PubMed ID: 32903557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
    Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VER-155008, a small molecule inhibitor of HSP70 with potent anti-cancer activity on lung cancer cell lines.
    Wen W; Liu W; Shao Y; Chen L
    Exp Biol Med (Maywood); 2014 May; 239(5):638-45. PubMed ID: 24676905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visualizing and Quantifying the Effect of the Inhibition of HSP70 on Breast Cancer Cells Based on Laser Scanning Microscopy.
    Yu B; Yang H; Zhang X; Li H
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818785274. PubMed ID: 30175665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
    Malek E; Driscoll JJ
    Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells.
    Selimovic D; Porzig BB; El-Khattouti A; Badura HE; Ahmad M; Ghanjati F; Santourlidis S; Haikel Y; Hassan M
    Cell Signal; 2013 Jan; 25(1):308-18. PubMed ID: 23079083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress.
    Wallington-Beddoe CT; Bennett MK; Vandyke K; Davies L; Zebol JR; Moretti PAB; Pitman MR; Hewett DR; Zannettino ACW; Pitson SM
    Oncotarget; 2017 Jul; 8(27):43602-43616. PubMed ID: 28467788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
    Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
    Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib.
    Neznanov N; Komarov AP; Neznanova L; Stanhope-Baker P; Gudkov AV
    Oncotarget; 2011 Mar; 2(3):209-21. PubMed ID: 21444945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
    Chen S; Dai Y; Pei XY; Myers J; Wang L; Kramer LB; Garnett M; Schwartz DM; Su F; Simmons GL; Richey JD; Larsen DG; Dent P; Orlowski RZ; Grant S
    Cancer Res; 2012 Aug; 72(16):4225-37. PubMed ID: 22693249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.
    Chauhan D; Li G; Podar K; Hideshima T; Shringarpure R; Catley L; Mitsiades C; Munshi N; Tai YT; Suh N; Gribble GW; Honda T; Schlossman R; Richardson P; Sporn MB; Anderson KC
    Blood; 2004 Apr; 103(8):3158-66. PubMed ID: 15070698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting HSP70 and GRP78 in canine osteosarcoma cells in combination with doxorubicin chemotherapy.
    Asling J; Morrison J; Mutsaers AJ
    Cell Stress Chaperones; 2016 Nov; 21(6):1065-1076. PubMed ID: 27631331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.
    Buontempo F; Orsini E; Lonetti A; Cappellini A; Chiarini F; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; Bertacchini J; Neri LM; McCubrey JA; Martelli AM
    Oncotarget; 2016 Jan; 7(2):1323-40. PubMed ID: 26593250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo.
    Zhou L; Zhang Y; Leng Y; Dai Y; Kmieciak M; Kramer L; Sharma K; Wang Y; Craun W; Grant S
    J Hematol Oncol; 2019 Mar; 12(1):25. PubMed ID: 30845975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.